Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Hanash 3-marker panel for Lung Cancer

Hanash 3-marker panel for Lung Cancer

Basics

Attributes

QA State: Accepted
Short Name:
HGNC Name:

The EDRN validation study ("Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques") presents evidence for the occurrence in lung cancer sera of autoantibodies to annexin 1, 14-3-3 theta and LAMR1, which precede the onset of symptoms and diagnosis. The combined AUC for these three antigens in CARET pre-clinical lung cancer sera vs. matched controls was 0.73. While autoantibodies to various cancer antigens have been reported in newly diagnosed lung cancer patient sera, an important aspect of this study is testing for occurrence of autoantibodies in pre-diagnostic sera and demonstration of significant autoantibody reactivity against LAMR1, annexin 1 and 14-3-3 theta.

Panel Details

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Three
QA State: Under Review

Overview

This study provides evidence for a predictive effect, in pre-diagnostic lung cancer sera, of a 3-biomarker panel for lung cancer. The panel is comprised of three antigens, annexin 1, LAMR1 and 14-3-3 theta.

Supporting Study Data

The following studies/protocols provide evidence supporting Hanash 3-marker panel for Lung Cancer indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Sensitivity/Specificity Information
Notes Sensitivity Specificity Prevalence NPV PPV
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 51.0 82.0 N/A N/A N/A
Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

Organs

No associated resources found.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.